With all the time and attention surrounding the BCMA-based products in multiple myeloma, including ADCs and CAR-T cell therapies, it’s easy to forget there are other approaches coming down the pike.
Beyond the hullabaloo there are various bispecific antibodies and T cell engagers in early stage development – not only is the modality different, but the targets might differ too.
How are all of these novel approaches doing in the clinic and how might they all fit together in future regimens? The myeloma world as we know it of proteasome inhibitors and IMiDs may not yet be a thing of the past, but the landscape is certainly changing.
In our third installment of the myeloma mini-series, we tackle these issues and look at near and medium term strategic directions, which can be considered and how these might impact different combination approaches and lines of therapy in order to further improve outcomes in this disease.